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ABSTRACT
Regular use of marijuana during adolescence enhances the risk of long-lasting neurobiological changes in adulthood.
The present study was aimed at assessing the effect of long-term administration of the synthetic cannabinoid
WIN55212.2 during adolescence in young adult mice. Adolescent mice aged 5weeks were subjected daily to the phar-
macological action of WIN55212.2 for 3weeks and were then left undisturbed in their home cage for a 5-week period
and finally evaluated by behavioral testing. Mice that received the drug during adolescence showed memory impair-
ment in the Morris water maze, as well as a dose-dependent memory impairment in fear conditioning. In addition,
the administration of 3mg/kg WIN55212.2 in adolescence increased adult hippocampal AEA levels and promoted
DNA hypermethylation at the intragenic region of the intracellular signaling modulator Rgs7, which was accompanied
by a lower rate of mRNA transcription of this gene, suggesting a potential causal relation. Although the concrete
mechanisms underlying the behavioral observations remain to be elucidated, we demonstrate that long-term admin-
istration of 3mg/kg of WIN during adolescence leads to increased endocannabinoid levels and altered Rgs7 expression
in adulthood and establish a potential link to epigenetic changes.
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INTRODUCTION
Adolescence is the most important stage of postnatal
neurodevelopment and covers distinct maturational
mechanisms in the corticolimbic circuitries (Powell
2006; Schneider 2013) including neuronal plasticity,
myelination, synaptic pruning, volumetric growth, pro-
gramming of neurotrophic levels and the maturation of
dopamine, glutamate and GABA neurotransmitters (Kilb,
2012; O’Donnell, 2010; Renard et al., 2014).
Clinical evidence indicates that the pathophysiology of
neuropsychiatric disorders is associated with dysfunc-
tions of the adolescent brain (Merikangas et al. 2009),
and this fact is aggravated when teenagers regularly
smoke marijuana (for review, see Hoch et al 2015).
Exposure to drugs of abuse during adolescence is par-
ticularly critical, and consumption during this time win-
dow has more dramatic consequences in later life when
compared to adulthood or juvenile drug exposure (for a
review of evidence in animals see Schneider 2013, for
human data see Hoch et al 2015). Several studies suggest
that abuse of the psychotropic component of marijuana
—Δ9-tetrahydrocannabinol (THC)—during adolescence
enhances the risk of long-lasting neurobiological changes
in the adult brain (Abush and Akirav, 2012; Renard
et al., 2013; Rubino et al., 2009). Long-lasting cognitive
impairments are in fact the most prominent effects after
chronic THC consumption during adulthood in humans
(for review, see Hoch et al 2015). Such impairments
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might be more serious following the use of synthetic can-
nabinoids, which are several fold more potent than THC
in activating its receptors in the brain, have become very
popular in recent years and whose consequences later in
life have not been investigated yet (Brents et al., 2011;
Schneir et al., 2012).
The endocannabinoid system (eCB), whose major
active component in learning-related areas such as the
hippocampus is the G-protein coupled receptor CB1, reg-
ulates axon innervation patterns during adolescence
(Eggan et al., 2010; Renard et al., 2013) and specifically
controls distinct neurodevelopmental processes, includ-
ing the proliferation and differentiation of progenitor
cells, neuronal migration, axonal guidance, fasciculation,
positioning of cortical interneurons, neurite outgrowth
and morphogenesis by acting at inhibitory and excitatory
synapses in brain regions involved in emotional or non-
emotional processes (for review see Harkany et al.,
2007, 2008).
Moreover, THC consumption can alter specific gene
programs by epigenetic mechanisms such as DNA meth-
ylation, histone modifications and chromatin
restructuring (for review, see D’Addario et al., 2013).
Most studies to date that addressed the role of epigenetic
mechanisms regarding the effects of exogenous cannabi-
noid drugs focused on adulthood (Tomasiewicz et al.,
2012; Watson et al., 2015). We are the first to evaluate
the effects of adolescent exposure to the synthetic canna-
binoid agonist WIN55212.2 (WIN) during adulthood in
relation with epigenetic alterations.
In particular, we focused on the effects of adolescent
WIN55212.2 exposure on DNA methylation (DNAme).
We chose this mark because it is a relatively stable mod-
ification that could persist during the withdrawal period
and explain the remote behavioral effects that the syn-
thetic cannabinoid WIN has after adolescent exposure.
DNAme provides a stable and potentially heritable epige-
netic component, moderates gene–environment interac-
tions (Rotter et al., 2012) and participates in normal
brain development (Wilson and Sengoku, 2013) and psy-
chiatric disorders (Tuesta and Zhang, 2014; Watson
et al., 2015). Most importantly, THC exposure has already
been linked to DNAme changes (for review, see Szutorisz
and Hurd, 2015), but the potential effects of DNAme al-
terations on remote cognitive performance after drug ex-
posure have not been deeply explored.
Given that CB1 receptors are highly expressed in the
hippocampal CA regions (Wang et al., 2003), which are
essential for learning and short-term as well as intermedi-
ate memory (Agis-Balboa and Fischer, 2014), we focused
on this region for the molecular characterization of the ef-
fects of adolescent exposure to WIN55212.2 on learning
and memory during adulthood. Because the most promi-
nent behavioral deficits reported in the current study
were found in those animals chronically treated with
either lowest or highest dose of the drug during adoles-
cence, we directed further investigation on
endocannabinoid content, epigenetic and transcriptional
gene regulation level under these conditions. We studied
Rgs7 as a candidate methylated gene for the following
reasons: RGS proteins are active regulators of G protein-
coupled receptors signaling (Sjögren, 2011; Xie and
Martemyanov, 2011), they are tightly regulated in
response to non-cannabinoid drugs of abuse (Holden
et al., 2014; Kach et al., 2012; Sjögren, 2011) and also in-
volved in hippocampus-dependent learning and memory
(Ostrovskaya et al., 2014). In brief, we report that 3weeks
ofWIN exposure during adolescence are enough to impair
hippocampus-dependent memory in adulthood. Further-
more, we show that endocannabinoid levels remain al-
tered in the adult hippocampus and also show that WIN
exposure results in persistent DNAme alterations that
could potentially be linked to transcriptional changes.
MATERIALS AND METHODS
All the procedures performed with mice were approved
by the Göttingen University Institutional Animal Care
and Use Committee and were in accordance with NIH
guidelines for the use of animals in research and the
European Communities Council Directive (86/609/EEC).
Animals
A total of 60 C57Bl6/J male mice aged 4weeks were ob-
tained from Charles River Laboratories (Sulzfeld,
Germany). On arrival, they were housed in groups of 5
and maintained under standard conditions (12-hour
light/dark cycle with 6:00/18:00 lights on/off, a room
temperature of 21±2 °C and food and water ad libitum).
One week after the habituation period, they were sub-
jected to the experiment (5weeks of age).
Drugs
The CB1/CB2 receptor agonist WIN55212.2 (WIN)
(Sigma-Aldrich, Seelze, Germany) was dissolved in a vehi-
cle solution consisting of 10 percent DMSO (Sigma-Al-
drich, Seelze, Germany) and 0.1 percent Tween80
(Sigma-Aldrich, Seelze, Germany) in 0.9 percent saline
and freshly prepared on the day of administration. The
same volume of drug or vehicle (200μl) was applied
intraperitoneally. The drug was administered at 0.5, 1
or 3mg/kg.
Experiment design and experimental groups
Mice were ascribed to one of four groups of 15 animals
each: vehicle, 0.5mg/kg (Low), 1mg/kg and 3mg/kg of
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WIN (High). Adolescent animals were subjected to daily
injections of vehicle or WIN for 3weeks (5–8weeks of
age). Then, animals were left undisturbed at their home
cage for 5weeks (withdrawal WIN treatment), and
finally young adult mice were evaluated by behavioral
testing (13weeks of age). Animals were sacrificed
immediately after the last behavioral paradigm. Animals
were deeply anesthetized by intraperitoneal injection of
2,2,2-tribromo-ethanol (Sigma-Aldrich, Hamburg,
Germany) and transcardially perfused with cool 0.1
percent saline phosphate buffer (PBS). The hippocampal
CA regions (≈ bregma 1.64 and interaural 2.16mm)
were freshly isolated and frozen in liquid nitrogen for
LC-MS, MEDIP-qPCR and quantitative RT-PCR (qRT-
PCR). See also Fig. S1.
Spatial memory
Morris water maze was performed in a circular pool of
1.2-m diameter and filled with opaque water. The plat-
form (11×11 cm) was placed in the center of the target
quadrant below the water level. The swimming pattern
was registered by a video camera device and tracked
using the VideoMot2 software (TSE, Bad Homburg,
Germany). For each training session, mice were subjected
to four consecutive trials. Each trial was started from a
different point of the pool, and the pattern was random-
ized for consecutive days. For each trial, animals were
allowed to search the platform for 60 seconds. If the plat-
form was not found, mice were guided to it and left on it
for 15 seconds before the next trial. Twenty-four hours
after the last training trial, mice memory was evaluated
(probe trial). In the probe trial, the platform was removed
from the pool, and the mice were allowed to swim for
60 seconds during which the time spent in the target
quadrant was registered as a measure of spatial memory.
N=15 mice/group.
Contextual fear memory
Associative learning was measured by use of NIR Video
Fear Conditioning system (Med Associates Inc., St.
Albans, USA). The training consisted of a single exposure
to the context (3minutes) followed by a tone [30 seconds,
10 kHz, 75-dB sound pressure level (SPL)] and a foot
shock (2 seconds, 0.7mA, constant current). The context
memory test was performed 24hours later by re-
exposing the mice for 3minutes to the conditioning con-
text. For the cued memory test, mice were put into a
novel context for 3minutes and after an initial 30 sec-
onds free of tone to evaluate context generalization, the
same training tone was played for 3minutes. Freezing
was automatically recorded by use of a video camera de-
vice coupled to computer equipped with VideoFreeze
software (Med Associates Inc., St. Albans, USA). N=15
mice/group.
General motor activity and anhedonia behavior
A distinct cohort of animals (n=15 mice/group) was sub-
jected to the same experimental procedure and then con-
secutively tested by open field and tail suspension to
elucidate plausible neurobiological effects of the long-term
administration of the cannabinoid agonist WIN on gen-
eral motor activity and anhedonia behavior, respectively.
In the open field test the spontaneous locomotor and ex-
ploratory activity of mice was monitored. The experiment
was conducted in a Plexiglas arena (45×45×55 cm).
Each animal was placed separately in the same start posi-
tion in the arena. Mice were allowed to explore the open
field for 10minutes without habituation time. Parameters
recorded were distance traveled, percent of time moving,
time spent in the center of open field (defined as 70 per-
cent of area), hyperactivity (forward movement with
speed greater than 20 cm/second) and number of
rearings. All parameters were analyzed automatically by
the ActiMot software (TSE, Bad Homburg, Germany) as
described before (Brzozka et al. 2011). Anhedonia was
evaluated by tail suspension test as described (Hayase T,
2011). Briefly, a cube of 35 cm each side with an open
front was used to perform the experiment. The mouse
was suspended by its tail in the center of the upper surface
using a tail hanger and non-irritating adhesive tape. The
cumulative immobility time during a 6-minute period
was manually registered by use of a timer.
Extraction and pre-purification procedures and
measurement of AEA, 2-AG, OEA and PEA levels
The endocannabinoids AEA and 2-AG, and the
endocannabinoid-related molecules N-palmitoylethano-
lamine (PEA) and N-oleoylethanolamine (OEA) were
extracted from the hippocampal CA regions and then pu-
rified from other lipids and quantified as described else-
where (Matias et al. 2008). First, tissues were dounce-
homogenized and extracted with chloroform/methanol/
Tris-HCl 50mM pH7.5 (2:1:1, v/v) containing internal
deuterated standards for AEA, 2-AG, PEA and OEA quan-
tification by isotope dilution ([2H]8AEA, [2H]52AG, [2H]
4 PEA, [2H]4 OEA) (Cayman Chemicals, MI, USA). The
lipid-containing organic phase was dried down, weighed
and pre-purified by open bed chromatography on silica
gel. Fractions were obtained by eluting the column with
99:1, 90:10 and 50:50 (v/v) chloroform/methanol. The
90:10 fraction was used for AEA, 2-AG, PEA and OEA
quantification by liquid chromatography-atmospheric
pressure chemical ionization-mass spectrometry (LC-
APCI-MS), as previously described and using selected
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ion monitoring at M+1 values for the four compounds
and their deuterated homologues, as described in Bisogno
et al. (2008). N=4 mice/group.
DNA and RNA extraction. Immunoprecipitation of the
methylated DNA
Total DNA and RNA were purified using the AllPrep
DNA/RNA Mini Kit (Qiagen, Düsseldorf, Germany).
DNA was sheared using a Bioruptor NGS (Diagenode) to
have a size distribution of 100 to 600 bp. Subsequently,
meDNA IP was carried out using Diagenode’s kit
(C02010020, Diagenode, Seraing, Belgium) according
to the manufacturer’s instructions.
RNA was digested with RNase-Free DNase (Qiagen,
Barcelona, Spain) and checked for integrity by capillary
gel electrophoresis (Bioanalyzer, Agilent Technologies,
Santa Clara, USA). The concentration of RNA was deter-
mined using a Nano-Drop® ND-1000 spectrophotometer
(Thermo Scientific, Wilmington, USA).
MEDIP-qPCR and quantitative RT-PCR
MEDIP-qPCR was performed using SYBR Green I Master
mix with custom primers (Rgs7 forward 5′-
GTTCCACTCACCAGAGGTCTCAG-3′ and reverse 5′-
TGCAGTACATAGGGAAGCAGAC-3′) (all from Applied
Biosystems, Darmstadt, Germany) on a CXF96TM Real-
Time PCR system (Bio-Rad, Hercules, USA). Quantitative
RT-PCR was performed using 1-μg RNA and was con-
verted to cDNA using the High-Capacity RNA-to-cDNA™
Kit (TermoFisher Scientific, Darmstadt, Germany). Mes-
senger RNA (mRNA) expression was quantified by qRT-
PCR using the CXF96TM Real-Time PCR system (Bio-
Rad, Hercules, USA). GAPDH mRNA was used as an en-
dogenous control. TaqMan primers and probes for mouse
Rgs7 cDNAs were obtained from validated and
predesigned Assays-on-Demand (Applied Biosystems,
Darmstadt, Germany) and used in real-time PCR amplifi-
cations to detect the expression of Rgs7.
The reactions were performed in triplicate using 2μl
of cDNA in a 10-μl reaction volume. Relative fold expres-
sion for each sample was calculated using the compara-
tive cycle threshold (Ct) method with 2ΔΔCt,
according to the manufacturer’s instructions (Applied
Biosystems, Darmstadt, Germany). Specific cDNAs were
quantified relative to a ‘calibrator’ control sample serving
as reference. The 2ΔΔCt for this ‘calibrator’ control
sample was arbitrarily set to 1. N=4 mice/group.
Statistical analysis
Statistical significance was evaluated by two-way ANOVA
or one-way ANOVA when applicable; individual compar-
isons were done using the Student’s t-test. A Bonferroni
post-hoc test was applied for the comparison of multiple
groups. A one sample t-test was used to determine
whether the sample mean was statistically different from
a known chance level. Nonparametric Mann–Whitney
U-test was used to analyze discrete variables. Pearson
correlation coefficients between behavioral data and dif-
ferentially methylated gene expression were properly cal-
culated. Significance values were set to p<0.05. In all
figures and text, data are represented as mean± SEM.
Significant effects were identified using Statistica
(StatSoft Software, Oklahoma, USA).
RESULTS
Cognitive impairment in mice chronically treated with
WIN during adolescence
In order to evaluate the effect of cannabinoid exposure
during adolescence in adulthood, we devised the follow-
ing experimental paradigm (Fig. S1): adolescent mice
were injected daily for 3weeks with either vehicle or
three increasing doses of WIN55212.2. They were then
left undisturbed for 5weeks and at 13weeks of age, and
they were tested for cognitive performance in the Morris
water maze and finally fear conditioning task.
All groups performed similarly during the training
phase of the water maze, as shown in the escape latency
patterns (Fig. 1a). However, two-way ANOVA analyses
for the escape latency revealed a significant main effect
for Drug (F(3, 112) = 3.68, p<0.05), Time (F(7, 112)
= 48.90, p<0.001), but not for the Time×Drug inter-
action (F(21, 112) =0.87, NS). Two-way ANOVA also
revealed no significant main effect for either Drug or
Time×Drug interaction in the distance traveled (F(3,
112) =1.55, NS; F(21, 112) =1.12, NS, respectively)
and swim speed (F(3, 112) =2.12, NS; F(21, 112)
= 0.83, NS, respectively), but a significant main effect
for Time in both distance traveled and swim speed
(F(7, 112) =67.77, p<0.001; F(7, 112) = 15.45,
p<0.001, respectively) (Fig. S2a). For the probe test, a
one-sample t-test against a chance level of 25 percent in-
dicated that control animals spent significantly more
than 25 percent of the probe test time in the target
quadrant (t(14) =4.68, p<0.001) which indicates ro-
bust memory for the location of the platform. In the
probe test, one-way ANOVA revealed significant WIN-
treatment effect for the number of target crossings
(F(3, 54) =3.17, p<0.05) (Fig. 1b), swim speed (F(3,
54) =4.73, p<0.01) (Fig. 1c), distance traveled (F(3,
54) =4.43, p<0.01) (Fig. 1d), percentage of time in
the target quadrant (F(3, 46) =7,55, p<0.01) and per-
centage of time spent in the rest of quadrants (F(3, 46)
= 7,55, p<0.01) (Fig. 1e). In fact, control mice
outperformed mice treated with WIN in a dose-
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Figure 1 Morris water maze test. (a) Two-way ANOVA analyses for the escape latency revealed a significant main effect for Drug (F(3, 112)
= 3.68, p< 0.05), Time (F(7, 112) = 48.90, p< 0.001), but not for the Time ×Drug interaction (F(21, 112) = 0.87, NS) during acquisition. (b–
e) For the probe test, one-way ANOVA revealed a significant main effect for the drug in the number of target crossings (F(3, 54) = 3.17,
p< 0.05), swim speed (F(3, 54) = 4.73, p< 0.01), distance traveled (F(3, 54) = 4.43, p< 0.01) and percentage of time in target quadrant (F
(3, 54) = 2.54, p< 0.05). (b) Control mice showed a significant number of crossings for the target quadrant when compared to animals treated
with 3 mg/kg of WIN (U= 2.15, p< 0.05). Those animals subjected to the pharmacological action of either 0.5, 1 or 3mg/kg of WIN displayed
a decrease in (c) swim speed (cm/second) (t(26) = 3.42; t(28) = 3.09; t(28) = 2.52; p< 0.05, respectively), (d) distance traveled (t(26) = 3.25;
t(28) = 3.08; t(28) = 2.52; p< 0.05, respectively) and (e) percent of time in target quadrant (t(21) = 4.22; t(21) = 4.03; t(22) = 5.04; p< 0.001,
respectively) in comparison to the control group. One-sample t-test against a chance level of 25 percent indicated that control animals spent
significantly more than 25 percent of the probe test time in the target quadrant (t(14) = 4.68, p< 0.001), which in turn, indicates robust mem-
ory for the location of the platform. Data are expressed as means ± SEM. P values were set as follows: *p< 0.05 and **p< 0.001. N= 15
mice/group
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dependent fashion, although the effect was only statisti-
cally significant for the 3mg/kg group, as indicated by
a significantly higher number of target crossings
(U=2.15, p<0.05) (Fig. 1b). Furthermore, those ani-
mals subjected to the pharmacological action of either
0.5, 1 or 3mg/kg of WIN displayed a decrease in the
swim speed (cm/second) (t(26) =3.42; t(28) =3.09;
t(28) =2.52; p<0.05, respectively) (Fig. 1c), distance
traveled (t(26) =3.25; t(28) = 3.08; t(28) =2.52;
p<0.05, respectively) (Fig. 1d) and percent of time in
target quadrant (t(21) =4.22; t(21) =4.03; t(22)
= 5.04; p<0.001, respectively) (Fig. 1e) in comparison
to the control group.
Animals treated with the drug exhibited slower swim-
ming activity during the probe test, but this fact was not
attributable to loss of interest (anhedonia) or deficits in
general motor activity. Indeed, no obvious differences in
the cumulative immobility time were found in the tail
suspension test (F(3, 55) = 0.67, NS) (Fig. S3a). There
were also no differences in the distance traveled (F(3,
54) =0.79, NS), time spent in center (F(3, 54) =0.33,
NS), hyperactive behavior (F(3, 54) =0.54, NS) and time
moving (F(3, 54) =1.04, NS) (Fig. S3b–e).
In order to establish whether the effect of WIN on
spatial memory is extensive to associative memory, we
tested mice in the fear conditioning paradigm. A one-
way ANOVA revealed significant differences by adminis-
tration of the drug during context (F(3, 54) =2.86,
p<0.05) and tone presentation (F(3, 54) =5.73,
p<0.01) (Fig. 2). Analogous to the effects seen on the
Morris water maze, mice showed a dose-dependent
impairment in contextual freezing behavior as indicated:
control versus 0.5mg/kg, t(26) =2.13, p<0.05; control
versus 1mg/kg, t(26) =2.03, p<0.05; control versus
3mg/kg, t(26) =3.23, p<0.001 (Fig. 2a). The response
to the tone (cued fear conditioning) was similarly
impaired in those animals treated with either 0.5
(t(26) = 2.65, p<0.01), 1 (t(28) =2.73, p<0.01) or
3mg/kg (t(28) =3.76, p<0.001) of the drug (Fig. 2b).
The administration of WIN during adolescence causes a
persistent increase in AEA levels in adulthood as well as
epigenetic and transcriptional alterations
Next, we examined the levels of endocannabinoids in
adult mice long after the exposure to WIN. One-way
ANOVA indicated that there were significant differences
in AEA (F(2, 11) =5.71, p<0.05) but not in 2-AG
(F(2, 11) =1.35, NS), PEA (F(2, 9) = 3.50, NS) and
OEA (F(2, 10) = 0.25, NS) content (Fig. 3). We found sig-
nificantly elevated AEA levels in the hippocampus of mice
treated with 3mg/kg of WIN in comparison to controls
(t(7) =2.28, p<0.05) and 0.5mg/kg of WIN (t(7)
=2.39, p<0.05) (Fig. 3a).
Finally, we argued that the remote behavioral and bio-
chemical changes observed in adulthood 5weeks after
drug exposure could be partly because of epigenetic
mechanisms. Such mechanisms have been reported in
association with drugs of abuse before (for review, see
Kalda and Zharkovsky, 2015) and are long-lasting
enough to explain the behavioral impairment described
above. We focused on DNAme because it has largely been
unexplored in the context of THC, especially as a poten-
tial mediator of long-lasting effects after adolescence ex-
posure. One-way ANOVA revealed a significant main
effect of the drug in the DNA methylation (F(2, 14)
= 17.17, p<0.001) and gene transcription of the candi-
date gene Rgs7 (F(2, 16) =4.40, p<0.05) (Fig. 4). We
found an increase in DNA methylation in an intragenic
region of Rgs7 gene in those animals treated with
3mg/kg of WIN when compared to controls (t(10)
=6.08, p<0.001) and animals treated with 0.5mg/
Figure 2 Pavlovian fear conditioning test. (a) Baseline freezing behavior followed a dose-dependent manner during a contextual fear condi-
tioning paradigm (F(3, 54) = 2.86, p< 0.05). In fact, controls exhibited elevated freezing behavior when compared to either 0.5 (t(26) = 2.13,
p< 0.05), 1 (t(26) = 2.03, p< 0.05) or 3mg/kg of WIN (t(26) = 3.23, p< 0.001). (b) During the tone presentation, ANOVA revealed a signif-
icant global effect of the drug (F(3, 54) = 5.73, p< 0.01). Control animals exhibited greater freezing behavior than mice exposed to either 0.5 (t
(26) = 2.65, p< 0.01), 1 (t(28) = 2.73, p< 0.01) or 3 mg/kg of WIN (t(28) = 3.76, p< 0.001). Data are expressed as means ± SEM. P values
were set as follows: *p< 0.05, **p< 0.01 and ***p< 0.001. N= 15 mice/group
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kg of WIN (t(10) =4.59, p<0.01), while animals ex-
posed to low dose of WIN exhibited a similar DNA meth-
ylation profile to controls (t(10) =1.65, NS) (Fig. 4a).
Interestingly, for the 3mg/kg treated animals, we also ob-
served a small but significant decrease in the mRNA
levels of Rgs7 (t(10) =2.05, p<0.05) indicating a
Figure 3 Endocannabinoid and endocannabinoid-related molecules in hippocampal CA regions. (a) The administration of 3 mg/kg of the drug
in adolescent animals increased hippocampal AEA levels in comparison to controls (t(7) =2.28, p< 0.05) and mice exposed to 0.5 mg/kg of
WIN (t(7) =2.39, p< 0.05) whereas (b–d) the concentration of 2-AG (F(2, 11) = 1.35, NS), PEA (F(2, 9) = 3.50, NS) and OEA (F(2, 10)
= 0.25, NS) were similar in all groups. Data are expressed as means ± SEM. P value was set at 0.05. N= 4 mice/group
Figure 4 MEDIP-qPCR and qRT-PCR. To characterize the role of methylated DNA (DNAme) in CA regions, we examined changes in
DNAme for Rgs7 shortly after the last behavioral paradigm. The one-way ANOVA revealed a significant main effect of the drug in the DNA
methylation (F(2, 14) = 17.17, p< 0.001) and gene transcription of the candidate gene Rgs7 (F(2, 16) = 4.40, p< 0.05). (a) We found the
DNA hypermethylation at the intragenic Rgs7 region in mice treated with 3 mg/kg of WIN when compared to controls (t(10) =6.08,
p< 0.001) and mice exposed to 0.5 mg/kg of WIN (t(10) =4.59, p< 0.01), whereas mice exposed to the lowest dose of WIN exhibited
a similar DNA methylation profile (t(10) =1.65, NS) when compared to controls. (b) The administration of 3mg/kg of WIN decreased
the expression of Rgs7 when compared to controls (t(10) = 2.05, p< 0.05). In contrast, mice subjected to 0.5 mg/kg displayed an increase in
Rgs7 expression when compared to either controls (t(12) =2.45, p< 0.05), potentially indicating compensatory effects or independent effec-
tor mechanisms for the low and high dosage of the drug. Data are expressed as means ± SEM. P values were set as follows: *p< 0.05, **p< 0.01
and ***p< 0.001. N= 4 mice/group. Rgs7, regulator of G protein signaling 7
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potential causal link to DNA hypermethylation in this lo-
cus (Fig. 4b). Strikingly however, we detected a signifi-
cant increase in Rgs7 mRNA levels in animals treated
with the lowest drug dose (t(12) =2.45, p<0.05)
(Fig. 4b), potentially indicating compensatory effects or
independent effector mechanisms for the low and high
dosage of the drug. None of the Person correlation coeffi-
cients revealed a significant association between behav-
ioral data and differentially methylated gene expression
(Fig. S4).
DISCUSSION
In mice, postnatal days 35–56 correspond to human ad-
olescent development (Dinieri and Hurd, 2012). Adoles-
cence covers a developmental period of psychosocial,
social and biological changes. Under normal physiologi-
cal conditions in adult mice, CB1 receptors and the levels
of endocannabinoid AEA and 2-AG are abundant in the
hippocampus (Di Marzo et al., 2000), a crucial structure
involved in learning and memory (for review, see
Zanettini et al., 2011).
The regular use of drugs of abuse during adolescence
has been associated with alterations in brain structure,
function and neurocognition. In fact, teenagers who fre-
quently smoke marijuana suffer dysfunctions in synaptic
pruning processes and display worse performance in
learning tests, cognitive flexibility, visual scanning, error
commission and working memory (Medina et al.,
2007a, 2007b; Nagel et al., 2005). Sometimes, the sum
of these mostly cognitive changes is named
‘Amotivational Syndrome’, and it can be the result of
chronic THC intoxication or long lasting effects of the
abuse of THC for longer periods of time, with unknown
pathophysiological mechanisms. Therefore, consumption
of THC during adolescence has adverse consequences in
later life in both human (Rubino and Parolaro, 2008)
and animal models (Jacobus and Tapert, 2014;
O’Tuathaigh et al., 2010; Rubino et al, 2009; Spear,
2013; Tantra et al., 2014). Adolescent rodents display
slower desensitization of CB1 receptors following chronic
treatment with WIN than adults (Abush and Akirav,
2012), and this fact might confer vulnerability to turn
into long-lasting effects. The current use of more potent
CB1 agonists, such as the many synthetic cannabinoids
found in the so-called spice drugs (Brents et al., 2011;
Schneir et al., 2012), which have potency and efficacy
higher than THC and comparable to WIN, the drug used
in the present study, might lead to even more dramatic
consequences.
In line with the present findings, long-term adminis-
tration of THC during adolescence causes persistent im-
pairments in short-term memory in rats (Abush and
Akirav, 2012) and deficits in fear conditioning during
adulthood in mice (Gleason et al., 2012). The adminis-
tration of marijuana-derived compounds interferes with
hippocampal inhibitory synapses and causes dysfunc-
tions in cognition and recall (Wilson and Nicoll
2002). In particular, the eCB system is involved in
memory acquisition, consolidation and retrieval of fear
(Ruehle et al., 2012). The elevation of the content of
AEA in the hippocampus is also associated with deficits
in learning and memory (Basavarajappa et al., 2014).
In agreement with this data, we found that animals
exposed to 3mg/kg of WIN displayed impairment in
both spatial and associative memory with a concomi-
tant increase in the levels of AEA in the CA hippocam-
pal subregion. However, none of the Pearson’s
comparisons revealed a significant associative effect
between behavioral and differentially methylated gene
expression. In order to validate the consequences of
the drug WIN at 3mg/kg on both spatial and associa-
tive memory, further investigation is required in the
model. The fact that we observe differences in the probe
trial but not during acquisition underpins a specific
effect of the drug on memory recall as previously
described (Wilson and Nicoll 2002).
Repeated exposure to psychostimulants induces epige-
netic changes including histone modification, DNA meth-
ylation and noncoding RNAs and concomitantly
behavioral dysfunctions (for review, see Kalda and
Zharkovsky, 2015). RGS proteins are potent negative reg-
ulators of neurotransmitter signaling via G protein-
coupled receptors (Sjögren, 2011; Xie and Martemyanov,
2011). Among the G-protein coupled receptors, the can-
nabinoid CB1 receptor is highly expressed in hippocampal
CA regions (Wang et al., 2003). Furthermore, several
RGS proteins are regulated in response to a different stim-
ulus, e.g. stress, drug exposure, changes in neurotrans-
mitter signaling, etc. (Holden et al., 2014; Kach et al.,
2012). In particular, RGS7 plays key roles in the regula-
tion of several biological processes such as vision, mem-
ory, motor control, reward behavior and nociception
(Anderson et al., 2009; Orlandi et al., 2015). Although
the mechanisms of this regulation remain to be eluci-
dated, we demonstrated that long-term administration
of 3mg/kg of WIN during mouse adolescence induces
DNA hypermethylation at the intragenic Rgs7 region
and concomitantly decreases the rate of transcription, po-
tentially contributing at least in part to the learning and
memory deficits as depicted in Fig. 5. The differential
dose-dependent response reported in this manuscript is
in line with our previous results (Tomas-Roig et al.,
2016). In brief, Tomas-Roig and colleagues (2016) found
that low dose of synthetic cannabinoid agonist possesses
a neuroprotective like effect while high dose of the drug
has a deleterious effect in the murine model of demyelin-
ation by cuprizone feeding.
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Ostrovskaya and colleagues (2014) determined that
Rgs7/ mice exhibited augmented GABABR signaling
in the hippocampus which resulted in selective deficits
in LTD and depotentiation, with normal LTP. LTP, LTD
and depotentiation are distinct forms of synaptic plastic-
ity implicated in hippocampal learning and memory-
related processes (Martin et al., 2000). Indeed, Rgs7 con-
trols synaptic plasticity while the lack of Rgs7 leads to a
disruption of learning and memory (Ostrovskaya et al.,
2014). In line with this evidence, we observed deficits
in hippocampus-dependent learning and memory pro-
cesses attributable potentially in part to declined gene ex-
pression levels of Rgs7 in young adults exposed to
3mg/kg of WIN during adolescence. Because all animals,
including vehicle-treated animals, were subjected to the
same behavioral battery and were handled exactly like
drug-injected animals, we are confident that the effects
on endocannabinoid and DNAme are associated with
the drug treatment.
Overall, we have shown that treatment with the syn-
thetic cannabinoid WIN during adolescence causes per-
sistent alterations in two behavioral paradigms during
adulthood: the Morris water maze and the fear condition-
ing test. We have also shown that these behavioral ab-
normalities are accompanied by a persistent increase in
AEA levels in the CA region of the hippocampus. Finally,
we found DNA hypermethylation at the Rgs7 locus,
alongside underregulation of the mRNA levels for the
same gene. Although the matter begs for further investi-
gation, we hypothesize that at least part of the persistent
effects of the drug may be driven by changes in DNA
methylation at specific loci within the hippocampus.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
Figure S1. Schematic drawing of the experiment. Ado-
lescent mice aged 5weeks were single daily subjected to
vehicle (control) or WIN55212.2 for 3weeks (treated),
then left undisturbed at their home cage for a 5-week
period (Withdrawal of WIN treatment) and finally evalu-
ated in Morris water maze and Pavlovian fear condition-
ing tests (n=15 mice/group). After behavioral testing,
the hippocampal CA regions (≈ bregma 1.64 and
interaural 2.16mm) were freshly isolated and frozen in
liquid nitrogen for LC-MS, MEDIP-qPCR and quantitative
RT-PCR (qRT-PCR). N=4 mice/group
Figure S2. Acquisition and memory phase in Morris Wa-
ter Maze paradigm. The locomotor activity during acqui-
sition was measured by the distance traveled and swim
speed while percent of time in target was recorded during
probe phase as a proof of learning memory. Briefly, all
mice were subjected to contextual-associative learning
for 8 days (acquisition) and 24hours after the last train-
ing session, mice memory was tested (probe test). Two-
way ANOVA revealed no significant main effect for either
Drug or Time×Drug interaction in (a) the distance trav-
eled (F(3, 112) =1.55, NS; F(21, 112) =1.12, NS, re-
spectively) and (b) swim speed (F(3, 112) =2.12, NS;
F(21, 112) =0.83, NS, respectively) during acquisition
phase. (c) For the probe test, one-way ANOVA indicates
a significant global effect of the drug in the percentage
of time spent in the target quadrant and also in the re-
maining quadrants (F(3, 46) =7,55, p<0.01). In fact,
those animals subjected to the pharmacological action
of either 0.5, 1 or 3mg/kg of WIN displayed a decrease
in the percent of time in target quadrant (t(21) = 4.22;
t(21) = 4.03; t(22) =5.04; p<0.001, respectively) when
compared to controls. Furthermore, one-sample t-test
against a chance level of 25 percent indicated that con-
trol animals spent significantly more than 25 percent of
the probe test time in the target quadrant (t(14) = 4.68,
p<0.001) which in turn, indicates robust memory for
the location of the platform. An * indicates significant dif-
ferences in the percentage of time in target between
WIN-treated groups and their respective controls. Level
of significance in one-sample t-test against a chance level
of 25 percent is represented by #. The significant differ-
ences in the percentage of time spent in other quadrants
between WIN-treated animals and the control group are
indicated by a +. Two symbols P value indicated
p<0.001. Data are expressed as means ± SEM. N=15
mice/group
Figure S3. General motor activity and anhedonia behav-
ior. A distinct cohort of mice were subjected to identical
experimental procedure and then evaluated by tail sus-
pension (TS) and open field (OF) paradigm. (a) The loss
of mice interest (anhedonia) was assessed by the cumula-
tive immobility time in the TS. (b–e) Mice were allowed to
explore the open field arena for 10minutes without ha-
bituation while locomotor and exploratory activities were
registered. One-way ANOVA did not reveal significant
global effects for WIN-treatment in (a) the cumulative
time immobile (F(3, 55) = 0.67, NS), (b) total distance
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traveled in center (F(3, 54) =0.79, NS), (c) time spent in
center (F(3, 54) =0.33, NS), (d) hyperactivity (F(3, 54)
= 0.54, NS) and (e) time moving (F(3, 54) =1.04, NS).
Data are expressed as means± SEM. N=15 mice/group
Figure S4. Scatter plot and correlation analysis. The de-
gree of association between behavioral and diferentialy
methylated Rgs7 gene expression was determined by
use of Pearson’s correlation coefficient. (a) Scatter plot
was used to illustrate the correlation between the
variables. (b) Contextual and cued fear conditioning-re-
lated variables as well as (c) general motor activity and
anhedonia behavior data were correlated with
differentialy methylated Rgs7 rate. None of the compari-
sons analysed by Pearson’s correlation test were signifi-
cant (See panel b and c). CTR, control; Low, mice
treated with 0.5mg/kg of WIN; High, mice treated with
3mg/kg of WIN. N=15 mice/group.
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